by The global In Situ Hybridization market size is expected to be worth around US$ 3.6 billion by 2030, according to a new report by Vision Research Reports.
The global In Situ Hybridization market size was valued at US$ 2,333.5 million in 2020 and is anticipated to grow at a CAGR of 9.9% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39036
Growth Factors
The market is gaining momentum in breast cancer with the FISH test. For instance, Roche offers a comprehensive ISH workflow solution with automated assay and digital pathology for breast cancer. Thus, increasing the scope of application is expected to drive the market to a major extend. In addition, technological advancements in instruments have fueled the market growth.
The COVID-19 is found to have a mixed impact on the market space. Social distancing mandates and lockdown policies have negatively affected the market to a considerable extent. However, the pandemic has opened new opportunities for operating entities by allowing them to deploy ISH methods in the R&D of COVID-19 related programs.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 3.6 billion by 2030 |
| Growth Rate | CAGR of 9.9% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Technology, Probe type, Application, Product, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | PerkinElmer, Inc.; Thermo Fisher Scientific Inc.; BioView; Agilent Technologies; Merck KGaA; Bio-Rad Laboratories, Inc.; Oxford Gene Technology; Leica BiosystemsNussloch GmbH; NeoGenomics Laboratories; Advanced Cell Diagnostics, Inc. |
By Technology Analysis
Based on technology, the FISH segment dominated the market for in situ hybridization and accounted for the largest revenue share of 53.9% in 2020. This can be attributed to the wide range of applications such as diagnosing congenital diseases including Edward’s Syndrome and Down’s Syndrome.
The CISH segment also captured a significant share of in situ hybridization over time as it is a cost-effective, reliable, and practical alternative for FISH. The technology aids in detecting HER-2/neu oncogene copies with conventional peroxidase reaction.
The affordable technological advancements in the ISH market are driving the segment growth. For instance, a group of researchers published their study in May 2021, suggesting that the chromogen-based RNA in situ hybridization approach is an effective method to detect druggable cytokines in atopic dermatitis and psoriasis.
By Probe Analysis
The DNA probe segment dominated the market for in situ hybridization and accounted for the largest revenue share of 51.1% in 2020. However, the RNA probe showcased a better growth rate in the forecasted period, owing to the development of new nucleic acid-based diagnostic assays and tools for analyzing DNA and RNA molecules.
RNA probe is used to detect the presence of complementary nucleic acid sequences by hybridization. The popularity of RNA as a hybridization tool is increasing owing to several advantages, such as the probes are synthesized by in vitro transcription and can be a replacement for DNA probes in almost all applications. The acceleration in the development of probe-based technology and products is anticipated to boost the growth of the ISH market.
By Product Analysis
The instruments segment dominated the market for in situ hybridization and accounted for the largest revenue share of 36.3% in 2020. The increasing demand for instruments is owing to the raising chains of diagnostic and research laboratories. Bio-Techne Corporation announced to introduce RNAscope technology along with new DNA scope assays in the commercial market.
On the other hand, the services segment is anticipated to witness significant growth in the market for in situ hybridization. Increasing outsourcing to improve operational functionalities and ensure high adherence to quality standards and is contributing toward the lucrative CAGR of this segment.
By Application Analysis
The cancer segment dominated the market for in situ hybridization and accounted for the largest revenue share of 36.4% in 2020. The increase in the incidence rate of cancer cases is anticipated to drive the growth.
Rising unhealthy lifestyle, aging population, health conditions, and environment are leading factors for causing cancers. Various organizations initiate research and promote further development in the treatment of cancers.
By End-use Analysis
The hospitals and diagnostic laboratories segment dominated the market for in situ hybridization and accounted for the largest revenue share of 48.8% in 2020. There are three major end-users in the market, hospitals and diagnostic laboratories, Contract Research Organizations (CROs), and academic and research institutions.
The ongoing pandemic can be the key driver for the laboratories as understanding the pathogen can offer a competitive advantage to the laboratories and assist to lead the industry.
Many organizations outsource their research and clinical trials to research laboratories and factors such as specialized workforce, deduces the cost for companies, and improving the efficiency can motivate companies and other organizations to outsource their research to the laboratories.
By Regional Analysis
North America dominated the In Situ Hybridization (ISH) market and accounted for the largest revenue share of 44.9% in 2020. This growth in the region can be attributed to the presence of a considerable number of market players and incentivized research projects by the regional government.
Asia Pacific, the market is likely to witness the fastest growth over the forecast period. Raising the attention of regional authorities in R&D is expected to be the key market driver over the forecast period. China and India are the fastest-growing markets in the Asia Pacific region.
Key Players
- Leica Biosystems Nussloch GmbH
- Merck KGaA
- Thermo Fisher Scientific
- Agilent Technologies
- BIO VIEW
- PerkinElmer, Inc.
- NeoGenomics Laboratories, Inc.
- Bio-Rad Laboratories, Inc.
- Oxford Gene Technology
- Advanced Cell Diagnostics, Inc.
Market Segmentation
- By Technology
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
- By Probe Type
- DNA
- RNA
- By Product
- Instruments
- Kits & Probes
- Software
- Services
- By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
- By End-use
- Hospitals & Diagnostic Laboratories
- CROs
- Academic& Research Institutes
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global In Situ Hybridization Market, By Technology
7.1. In Situ Hybridization Market, by Technology, 2021-2030
7.1.1. Fluorescent In Situ Hybridization (FISH)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Chromogenic In Situ Hybridization (CISH)
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global In Situ Hybridization Market, By Probe Type
8.1. In Situ Hybridization Market, by Probe Type, 2021-2030
8.1.1. DNA
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. RNA
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global In Situ Hybridization Market, By Product
9.1. In Situ Hybridization Market, by Product, 2021-2030
9.1.1. Instruments
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Kits & Probes
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Software
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Services
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global In Situ Hybridization Market, By Application
10.1. In Situ Hybridization Market, by Application, 2021-2030
10.1.1. Cancer
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Cytogenetics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Developmental Biology
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Infectious Diseases
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global In Situ Hybridization Market, By End-use
11.1. In Situ Hybridization Market, by End-use, 2021-2030
11.1.1. Hospitals & Diagnostic Laboratories
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. CROs
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Academic& Research Institutes
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global In Situ Hybridization Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology (2017-2030)
12.1.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.1.3. Market Revenue and Forecast, by Product (2017-2030)
12.1.4. Market Revenue and Forecast, by Application (2017-2030)
12.1.5. Market Revenue and Forecast, by End-use (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Technology (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, by Technology (2017-2030)
12.1.7.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.1.7.3. Market Revenue and Forecast, by Product (2017-2030)
12.1.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.1.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology (2017-2030)
12.2.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.2.3. Market Revenue and Forecast, by Product (2017-2030)
12.2.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, by Technology (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, by Technology (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Product (2017-2030)
12.2.9.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology (2017-2030)
12.3.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.3.3. Market Revenue and Forecast, by Product (2017-2030)
12.3.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, by Technology (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, by Technology (2017-2030)
12.3.9.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.3.9.3. Market Revenue and Forecast, by Product (2017-2030)
12.3.9.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology (2017-2030)
12.4.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.4.3. Market Revenue and Forecast, by Product (2017-2030)
12.4.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, by Technology (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, by Technology (2017-2030)
12.4.9.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.4.9.3. Market Revenue and Forecast, by Product (2017-2030)
12.4.9.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology (2017-2030)
12.5.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.5.3. Market Revenue and Forecast, by Product (2017-2030)
12.5.4. Market Revenue and Forecast, by Application (2017-2030)
12.5.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Technology (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, by Technology (2017-2030)
12.5.7.2. Market Revenue and Forecast, by Probe Type (2017-2030)
12.5.7.3. Market Revenue and Forecast, by Product (2017-2030)
12.5.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.5.7.5. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 13. Company Profiles
13.1. Leica Biosystems Nussloch GmbH
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck KGaA
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Thermo Fisher Scientific
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Agilent Technologies
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BIO VIEW
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. PerkinElmer, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. NeoGenomics Laboratories, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bio-Rad Laboratories, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Oxford Gene Technology
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Advanced Cell Diagnostics, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39036
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
